Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine

Zheng Quan Toh; Beth Temple; Tran Ngoc Huu; Vo Thi Trang Dai; Nguyen Trong Toan; Doan Y Uyen; Kathryn Bright; Lien Anh Ha Do; E Kim Mulholland; Paul V Licciardi

doi:10.1038/s41541-020-00225-z

Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine

NPJ Vaccines. 2020 Aug 18:5:76. doi: 10.1038/s41541-020-00225-z. eCollection 2020.

Authors

Zheng Quan Toh^{1

2}, Beth Temple^{1

3

4}, Tran Ngoc Huu⁵, Vo Thi Trang Dai⁵, Nguyen Trong Toan⁶, Doan Y Uyen⁶, Kathryn Bright¹, Lien Anh Ha Do^{1

2}, E Kim Mulholland^{1

2

4}, Paul V Licciardi^{1

2}

Affiliations

¹ New Vaccines, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC Australia.
² Department of Paediatrics, The University of Melbourne, Parkville, VIC Australia.
³ Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT Australia.
⁴ Department of Infectious Disease and Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
⁵ Microbiology and Immunology, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
⁶ Department of Disease Control and Prevention, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.

Abstract

This brief communication describes the findings from a randomised controlled trial in Vietnam that co-administration of measles vaccine (MV) with 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix®, GSK) does not affect the immunogenicity of MV. These findings are most relevant for low- and middle-income countries (LMICs) in Asia considering PCV introduction.

Keywords: Public health; Translational research; Vaccines.